Inovio Pharmaceuticals Company
Inovio Pharmaceuticals engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline include VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP.
Investors
Headquarters:
United States
Funding Status:
N/A
Employee Number:
N/A
Investment Stage:
N/A
Number Of Exists:
N/A
Technology:
COVID
Investor Type:
N/A
Founded Date:
N/A
Industry:
Genomic and Epigenominc Instabillity